The effects of special patient population plasma on pharmacokinetic quantifications using LC-MS/MS.
Sign Up to like & getrecommendations! Published in 2019 at "Drug metabolism letters"
DOI: 10.2174/1872312813666191015162634
Abstract: BACKGROUND Clinical development of lesinurad, a selective uric acid reabsorption inhibitor, required analysis of lesinurad in plasma from special patient populations. EMA and FDA bioanalytical method validation guidance have recommended studying matrix effects on quantitation… read more here.
Keywords: plasma; effects special; special patient; lesinurad plasma ... See more keywords